Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| bit.bio | 2026 | Series C | $50.0M | Cambridge |
| Parabilis Medicines | 2026 | Series F | $305.0M | Cambridge |
| SciNeuro | 2025 | Venture - Series Unknown | $53.0M | Rockville |
| Paradigm | 2025 | Series B | $78.0M | New York |
| Elephas | 2025 | Venture - Series Unknown | $40.0M | Madison |
| Synchron | 2025 | Series D | $200.0M | Brooklyn |
| Mirador Therapeutics | 2026 | Series B | $250.0M | San Diego |
| Aspen Neuroscience | 2025 | Series C | $115.0M | San Diego |
| Lifordi Immunotherapeutics | 2025 | Venture - Series Unknown | $42.0M | Burlington |
| Gate Bioscience | 2025 | Series B | $65.0M | Brisbane |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 26 | bit.bio | Series C | $50.0M | Cambridge, United Kingdom |
| 27 | Parabilis Medicines | Series F | $305.0M | Cambridge, United States |
| 28 | SciNeuro | Venture - Series Unknown | $53.0M | Rockville, United States |
| 29 | Paradigm | Series B | $78.0M | New York, United States |
| 30 | Elephas | Venture - Series Unknown | $40.0M | Madison, United States |
| 31 | Synchron | Series D | $200.0M | Brooklyn, United States |
| 32 | Mirador Therapeutics | Series B | $250.0M | San Diego, United States |
| 33 | Aspen Neuroscience | Series C | $115.0M | San Diego, United States |
| 34 | Lifordi Immunotherapeutics | Venture - Series Unknown | $42.0M | Burlington, United States |
| 35 | Gate Bioscience | Series B | $65.0M | Brisbane, United States |
Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development.
Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.
SciNeuro is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases.
Paradigm creates a platform that allow all patients to participate in clinical trials while also enhancing trial efficiency.
Elephas harnesses latest advances in cancer biology, multimodal microscopy, and artificial intelligence to empower clinical decision-making.
Synchron is a bioelectronics medicine company that develops neuromodulation solutions for previously-untreatable nervous system conditions.
Mirador Therapeutics develops precision medicines for immune-mediated diseases.
Aspen Neuroscience is a biotechnology company that specializes in personalized cell therapies and autologous regenerative medicine.
Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders.
Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.
Atlas Data Storage is an information technology company focused on data storage solutions.
Seaport Therapeutics is a clinical-stage biopharmaceutical company that develops neuropsychiatric medicines.
Salma Health is a concierge neurocognitive clinic that uses neurology and psychiatry techniques to solve various brain conditions.
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Syndex Bio is a biotechnology platform offering molecular technologies and AI for the diagnosis and treatment of disease.
Vizgen provides spatial multi-omics platforms enabling researchers to reveal cellular insights through spatial transcriptomics proteomics.
Designing innovative technologies focused on accelerating global access to biotherapeutics.
Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies to treat autoimmune and inflammatory diseases.
Pelage Pharma is a regenerative medicine biotechnology company developing treatments for hair loss.
Kardigan develops personalized medicines using AI and data to target and treat the root causes of cardiovascular diseases.
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.
Ollin Biosciences operates as a clinical-stage biopharmaceutical company.
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.
ARCH Venture Partners has invested in 156 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
ARCH Venture Partners's top investment sectors include Biotechnology, Medical, Health Care, Therapeutics, Biopharma. The firm invests across 21 different industry categories.
Among tracked funding rounds, Parabilis Medicines received $305.0M in a Series F round. ARCH Venture Partners's total known invested capital is $14.3B.
ARCH Venture Partners's average investment size is $119.8M across its portfolio of 156 companies.
Recent ARCH Venture Partners portfolio additions include bit.bio, Parabilis Medicines, SciNeuro, Paradigm, Elephas. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors